Mar 6, 2026 08:45AM
Mar 2, 2026 01:10AM
Feb 20, 2026 02:00AM
Feb 20, 2026 02:00AM
Feb 20, 2026 01:05AM
Feb 16, 2026 01:00AM
Feb 7, 2026 03:40PM Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
Dec 22, 2025 01:01AM
Dec 22, 2025 01:00AM
Dec 16, 2025 08:30AM
Dec 8, 2025 04:30PM
Nov 10, 2025 01:10AM
Nov 3, 2025 09:00AM
Nov 3, 2025 01:00AM Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
Oct 28, 2025 02:00AM
Oct 23, 2025 09:00AM
Oct 20, 2025 01:05AM
Oct 20, 2025 01:01AM
Oct 20, 2025 01:00AM
Oct 16, 2025 11:49AM
Oct 16, 2025 11:45AM Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
Oct 13, 2025 09:00AM
Oct 13, 2025 01:05AM
Oct 2, 2025 06:30PM
Oct 2, 2025 06:30PM
Sep 24, 2025 02:30AM
Sep 18, 2025 10:00AM
Sep 5, 2025 01:00AM New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
Aug 30, 2025 10:30AM
Aug 4, 2025 08:00AM
Aug 1, 2025 02:00PM
Jul 28, 2025 01:00AM
Jul 24, 2025 09:00AM
Jul 18, 2025 11:45AM
Jul 18, 2025 11:45AM Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jun 20, 2025 11:48AM
Jun 20, 2025 11:45AM
Jun 16, 2025 11:30AM
Jun 2, 2025 04:05PM
May 31, 2025 08:05AM
May 30, 2025 01:00AM
May 23, 2025 01:00AM New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
May 22, 2025 11:45AM
May 20, 2025 02:58PM
May 13, 2025 01:00AM
Apr 25, 2025 01:00AM
Apr 2, 2025 11:45AM
Mar 5, 2025 01:00AM
Mar 3, 2025 11:45AM FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Feb 12, 2025 11:45AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All